Biocon growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+10.9%+14.8%
EBITDA+9.1%+11.2%
Net Income−74.2%−16.9%
EPS (adj.)−62.0%−5.9%
Total Assets+8.3%+6.9%
Total Equity+32.2%+17.6%
Free Cash Flow−95.2%−13.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BIOCON₹350.70

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹56,848 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+10.9+14.8
EBITDA+9.1+11.2
Net Income-74.2-16.9
EPS (adj.)-62.0-5.9
Total Assets+8.3+6.9
Total Equity+32.2+17.6
Free Cash Flow-95.2-13.3
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.